This study demonstrates that activation of α7nAChR could decrease on-site mortality in crush syndrome based on the decline of serum potassium through insulin signaling-Na/K-ATPase pathway (Figure 8). This evidence concerns the gene CHRNA7 and Crush Syndrome.